This article is more than 5 years old. Information may no longer be current.
Investigational drug reduced mortality in patients with acute HF
Click Here to Manage Email Alerts
Phase 3 data from the RELAX-AHF study demonstrate that RLX030, a recombinant form of the human hormone relaxin-2, reduced all-cause mortality in patients with acute HF.
According to a statement released today by Novartis, investigational RLX030 (serelaxin) was well tolerated in this patient population. The RELAX-AHF study had two primary endpoints using different scales to measure reduction in dyspnea, only one of which reached statistical significance, according to the press release.
The full results will be presented at the American Heart Association Scientific Sessions in November.
RELAX-AHF was designed to investigate the efficacy and safety of RLX030 for the treatment of acute HF. The randomized, double blind, placebo-controlled study involves 1,161 patients in 11 countries. The drug was administered on admission via IV infusion for up to 48 hours, in addition to loop diuretics and other medications, and was compared with placebo on top of standard of care treatment for acute HF.